BC Innovations | Oct 25, 2018
Distillery Therapeutics

Neurology

INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than...
BC Innovations | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound that...
BC Innovations | Feb 21, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Free fatty acid receptor 1 (FFAR1; GPR40) Studies in mice suggest GPR40 agonists could help prevent bone...
BC Innovations | Jan 31, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) In vitro and mouse studies identified an alkyne series of FFAR1 agonists that could help treat...
BC Innovations | Aug 9, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) Mouse and in vitro studies have identified GPR40 agonists that could help treat type 2 diabetes....
BC Innovations | Feb 16, 2012
Targets & Mechanisms

Still un-sirtuin

Researchers at the NIH have proposed a new mechanism to explain the beneficial metabolic effects of resveratrol, a polyphenol compound from red wine thought by many to act primarily on sirtuin 1 . The NIH team...
BioCentury | Aug 22, 2011
Product Development

Beta testing GPR40

With concerns about cardiovascular safety and cancer signals dampening optimism about the future of diabetes therapies, there is an emerging race to demonstrate that activating free fatty acid receptor 1 can avoid such safety issues...
BC Week In Review | Jul 4, 2011
Clinical News

Connexios preclinical data

In prediabetic rats, oral CNX-011-67 for 7 weeks significantly enhanced insulin secretion and delayed the onset of fasting glycemia vs. vehicle-treated controls (p<0.01 for both). The free fatty acid receptor 1 ( FFAR1 ; GPR40 ) agonist...
BioCentury | Apr 12, 2010
Strategy

Stahel sees Scale in India

Indian biotech Connexios Life Sciences Pvt. Ltd. is hoping to pattern itself after Western R&D-focused biotechs by building a pipeline of compounds against novel targets backed by a strong understanding of disease biology. The scale...
BC Week In Review | Mar 8, 2010
Company News

Connexios board of directors update

Connexios Life Sciences Pvt. Ltd. , Bangalore, India   Business: Endocrine, Metabolic   Appointed: Rolf Stahel as chairman, formerly CEO of Shire plc  ...
Items per page:
1 - 10 of 11
BC Innovations | Oct 25, 2018
Distillery Therapeutics

Neurology

INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than...
BC Innovations | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound that...
BC Innovations | Feb 21, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Free fatty acid receptor 1 (FFAR1; GPR40) Studies in mice suggest GPR40 agonists could help prevent bone...
BC Innovations | Jan 31, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) In vitro and mouse studies identified an alkyne series of FFAR1 agonists that could help treat...
BC Innovations | Aug 9, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) Mouse and in vitro studies have identified GPR40 agonists that could help treat type 2 diabetes....
BC Innovations | Feb 16, 2012
Targets & Mechanisms

Still un-sirtuin

Researchers at the NIH have proposed a new mechanism to explain the beneficial metabolic effects of resveratrol, a polyphenol compound from red wine thought by many to act primarily on sirtuin 1 . The NIH team...
BioCentury | Aug 22, 2011
Product Development

Beta testing GPR40

With concerns about cardiovascular safety and cancer signals dampening optimism about the future of diabetes therapies, there is an emerging race to demonstrate that activating free fatty acid receptor 1 can avoid such safety issues...
BC Week In Review | Jul 4, 2011
Clinical News

Connexios preclinical data

In prediabetic rats, oral CNX-011-67 for 7 weeks significantly enhanced insulin secretion and delayed the onset of fasting glycemia vs. vehicle-treated controls (p<0.01 for both). The free fatty acid receptor 1 ( FFAR1 ; GPR40 ) agonist...
BioCentury | Apr 12, 2010
Strategy

Stahel sees Scale in India

Indian biotech Connexios Life Sciences Pvt. Ltd. is hoping to pattern itself after Western R&D-focused biotechs by building a pipeline of compounds against novel targets backed by a strong understanding of disease biology. The scale...
BC Week In Review | Mar 8, 2010
Company News

Connexios board of directors update

Connexios Life Sciences Pvt. Ltd. , Bangalore, India   Business: Endocrine, Metabolic   Appointed: Rolf Stahel as chairman, formerly CEO of Shire plc  ...
Items per page:
1 - 10 of 11